Fidelio acquires Indical Bioscience
Fidelio acquires Indical Bioscience, a leading provider of diagnostic products specifically developed for veterinary specific applications.
The company develops and markets diagnostic solutions and products based on PCR (molecular) and ELISA (immunodiagnostic) technology. The products are used by laboratories primarily to indicate and diagnose viruses and bacteria in production animals, to counteract proliferation and contribute to better animal and human health.
Indical Bioscience is based in Germany and serves customers in 169 countries through its own sales force and commercial partners. Fidelio Capital acquired Indical Bioscience through a carve-out from Qiagen, a molecular diagnostic group listed on the NYSE and Frankfurt stock exchanges.
All news and storiesMore news
All news and stories
KEYTO Group establishes home security as a new business vertical
KEYTO Group continues to broaden its home services offering with a new vertical in home security. The first company to be added is the Swedish company Säkra Larm.
Read more →
Audria expands into the UK with Tandem Property
Audria, a tech-driven real estate-services platform, expands into the UK with the addition of Tandem Property. Tandem Property provides property and asset management solutions, and is the fifth company to join Audria, following Newsec, Novier, Sveaviken and Avy.
Read more →Audria strengthens its real estate services offering with the addition of Novier
Audria, which brings together leading real estate services companies with a focus on technology, AI and international growth, strengthens its offering with the addition of Novier.
Read more →